Biomarkers predict thromboembolism risk, mortality among people with cancer, COVID-19

ByAshley Killen

ByAlok A. Khorana, MD

Fact checked byMindy Valcarcel, MS

NEW ORLEANS — Patients with cancer and COVID-19 exhibited a 3% risk for thromboembolism within 30 days of their first positive test, according to study results presented at ASH Annual Meeting and Exposition.

Hemostatic biomarkers at baseline — such as von Willebrand factor and factor VIII — appeared predictive for thromboembolism, hospitalization and 90-day mortality, results of the prospective longitudinal cohort study showed.

The findings could be used to identify patients with cancer and COVID-19 who may be at elevated risk for poor outcomes, researchers concluded.

Investigator Alok A. Khorana, MD, director of the gastrointestinal malignancies program at Cleveland Clinic, as well as Sondra and Stephen Hardis chair in oncology research and vice chair for clinical services at Taussig Cancer Institute, spoke with Healio about the study results and their potential implications.

Published by:

Sources/Disclosures

Collapse

Source:

Khorana AA, et al. Abstract 136. Presented at: ASH Annual Meeting and Exposition; Dec. 10-13, 2022; New Orleans.

Disclosures: Khorana reports consulting roles with or honoraria from Anthos Therapeutics, Bayer, Bristol Myers Squibb, Janssen, Pfizer and Sanofi. Please see the abstract for all other researchers’ relevant financial disclosures.

ASH Annual Meeting and Exposition

Read more

Biomarkers predict thromboembolism risk, mortality among people with cancer, COVID-19

Related Content